Shots:
- Precision to receive $100M upfront, $35M as an equity investment and will receive $420M as milestones/ product along with royalties on sales of licensed products emerges from the collaboration
- Precision will lead to pre-clinical research and IND-enabling activities while Lilly will lead clinical development and commercialization and have the right to select up to 3 additional gene targets. Precision can co-fund clinical development of one product in exchange for an increased royalty rate on co-funded product sales
- The agreement will utilize Precision’s ARCUS genome editing platform for the development of in vivo therapies for genetic disorders, focusing on DMD and two other undisclosed gene targets
Click here to read full press release/ article | Ref: Lilly | Image: KMS Lighthouse
The post Eli Lilly Signs an Exclusive Agreement with Precision BioSciences on Genome Editing Research first appeared on PharmaShots.
